In conclusion, by inhibiting hepatic macrophage aggregation and promoting apoptosis, CHI3L1 deficiency could ameliorate hepatic fibrosis; thus,CHI3L1 can serve as a potential therapeutic target for liver fibrosis. Here, CHI3L1 is linked to Hepatic fibrosis.